Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer

Bean, 2007, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib, Proc Natl Acad Sci U S A, 104, 20932, 10.1073/pnas.0710370104 Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478 Lai, 2019, Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer, J Clin Oncol, 37, 876, 10.1200/JCO.18.00177 Ou, 2016, High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression, Lung Cancer, 98, 59, 10.1016/j.lungcan.2016.05.015 Organ, 2011, An overview of the c-MET signaling pathway, Ther Adv Med Oncol, 3, S7, 10.1177/1758834011422556 Zhou, 2009, Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, Nature, 462, 1070, 10.1038/nature08622 Cappuzzo, 2009, Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients, J Clin Oncol, 27, 1667, 10.1200/JCO.2008.19.1635 Schildhaus, 2015, MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung, Clin Cancer Res, 21, 907, 10.1158/1078-0432.CCR-14-0450 Yang, 2013, Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naive Asian NSCLC patients, Int J Cancer, 132, E74, 10.1002/ijc.27813 Wang, 2018, Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib, Lung Cancer, 118, 105, 10.1016/j.lungcan.2018.02.007 Li, 2019, Combined use of crizotinib and gefitinib in advanced lung adenocarcinoma with leptomeningeal metastases harboring MET amplification after the development of gefitinib resistance: a case report and literature review, Clin Lung Cancer, 20, e251, 10.1016/j.cllc.2018.12.004 Wang, 2019, Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study, J Transl Med, 17, 52, 10.1186/s12967-019-1803-9 Deng, 2018, Response to dual crizotinib and osimertinib treatment in a lung cancer patient with MET amplification detected by liquid biopsy who acquired secondary resistance to EGFR tyrosine kinase inhibition, J Thorac Oncol, 13, e169, 10.1016/j.jtho.2018.04.007 Zheng, 2019, Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: successful treatment with gefitinib and crizotinib, Lung Cancer, 129, 72, 10.1016/j.lungcan.2019.01.009 Gu, 2021, Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib, Curr Probl Cancer, 45, 100702, 10.1016/j.currproblcancer.2020.100702 Gainor, 2016, Dramatic response to combination erlotinib and crizotinib in a patient with advanced, EGFR-mutant lung cancer harboring de novo MET amplification, J Thorac Oncol, 11, e83, 10.1016/j.jtho.2016.02.021 Wu, 2020, Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial, Lancet Respir Med, 8, 1132, 10.1016/S2213-2600(20)30154-5 Sequist, 2020, Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study, Lancet Oncol, 21, 373, 10.1016/S1470-2045(19)30785-5 Yang, 2021, A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer, Invest New Drugs, 39, 477, 10.1007/s10637-020-01010-4 Mao, 2017, Capture-based targeted ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung cancer, J Thorac Oncol, 12, 663, 10.1016/j.jtho.2016.11.2235 Ou, 2011, Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification, J Thorac Oncol, 6, 942, 10.1097/JTO.0b013e31821528d3 Camidge, 2018, Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): updated safety and efficacy findings from a phase 1 trial, J Clin Oncol, 36, 9062, 10.1200/JCO.2018.36.15_suppl.9062 Cappuzzo, 2009, MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients, Ann Oncol, 20, 298, 10.1093/annonc/mdn635 Wang, 2019, Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations, Cancer Commun (Lond), 39, 7, 10.1186/s40880-019-0354-z Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530 Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X Han, 2017, Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial, Int J Cancer, 141, 1249, 10.1002/ijc.30806 Spigel, 2017, Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung, J Clin Oncol, 35, 412, 10.1200/JCO.2016.69.2160 Guo, 2019, MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: data from a tri-institutional cohort of the Lung Cancer Mutation Consortium, J Thorac Oncol, 14, 1666, 10.1016/j.jtho.2019.06.009 Saigi, 2018, Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer, Clin Transl Oncol, 20, 881, 10.1007/s12094-017-1799-7 Cheng, 2020, Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: a single-center retrospective study, Lung Cancer, 150, 97, 10.1016/j.lungcan.2020.10.010 Li, 2020, Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing, Lung Cancer, 149, 17, 10.1016/j.lungcan.2020.08.021